Form 4: Tivic Health Director Granted Stock Options

Tivic Health Systems, Inc. director Sheryle Bolton was granted 12,500 stock options with an exercise price of $3.32, vesting over one year.

Summary

• Director Sheryle Bolton of Tivic Health Systems, Inc. (TIVC) was granted 12,500 stock options.
• The stock options have an exercise price of $3.32 per share.
• The grant date for these options is August 6, 2025.
• The options will vest in four successive equal quarterly installments, with 100% vesting upon the first anniversary of the grant date.
• The expiration date for these options is August 5, 2035.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of stock options to a director is a routine corporate governance action aimed at aligning interests. It's not a major financial event but indicates ongoing compensation practices.

Positives

• Granting of stock options to a director aligns their interests with shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long window for potential value realization.

Negatives

• No immediate cash benefit to the director; value is contingent on future stock price appreciation above the exercise price.

Risks

• The value of the stock options is subject to the future market performance of Tivic Health Systems, Inc.'s common stock.
• If the stock price does not exceed the exercise price of $3.32, the options may expire worthless.
• Potential for minor dilution for existing shareholders if options are exercised and new shares are issued.

Future Outlook

The stock options are granted with a future effective date of August 6, 2025, and are designed to vest over the subsequent year, aligning the director's incentives with the company's long-term performance.

Industry Context

This is a standard insider transaction filing (Form 4) reporting an equity grant to a director. Such grants are common practice across industries to incentivize leadership and align their interests with shareholder value creation.

Comparison to Industry Standards

• Granting stock options to directors is a common compensation practice in the technology and healthcare sectors, similar to companies like Medtronic or Abbott Laboratories, which often use equity incentives to retain and motivate key personnel.
• The vesting schedule of one year (four quarterly installments) is a relatively short vesting period compared to typical employee stock options which might vest over 3-4 years, but it is common for director grants to have shorter or immediate vesting.
• The 10-year expiration period for the options is standard for long-term incentive plans.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also potential for increased long-term value creation due to aligned director incentives.

Next Steps

• The stock options will begin vesting in four equal quarterly installments from August 6, 2025.
• Full vesting of the options is expected by August 6, 2026 (first anniversary of grant date).

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a director as part of their compensation. It does not contain new information regarding the company's financial performance, strategic direction, or significant operational changes that would warrant a change in investment recommendation. The grant aligns director incentives with shareholder value, which is a positive, but it's not a catalyst for a 'buy' or 'sell' decision.

Keywords

Tivic Health Systems, TIVC, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Beneficial Ownership